| The EAAGIGILTV peptide is derived from the Melan-A/MART-1 antigen, a melanoma-associated protein. Presented by HLA-A*02:01, it is recognized by CD8+ T cells and is a key target in melanoma immunotherapy. This epitope is widely used in cancer vaccine research, adoptive T cell therapies, and studies aiming to enhance anti-tumor immune responses. |
